TRANSCATHETER MITRAL VALVE IMPLANTATION: HOW TO DO IT?

Abstract

Half of the patients with severe symptomatic MR is not referred for surgery, either due to frailty, multiple comorbidities, or prohibitively high surgical risk. The mortality rate in this cohort of patients reaches 50% at 5 years of follow-up, and up to 90% of surviving patients had at least 1 hospitalization for heart failure within the 5 years. By avoiding the morbidity of open mitral replacement and effectively preventing recurrence of MR, transcatheter mitral valve implantation (TMVI) could provide the best option for treating mitral valve disease.